arcutis
completes
enrollment
pivotal
phase
clinical
trials
evaluating
topical
roflumilast
cream
potential
treatment
plaque
psoriasis
roflumilast
cream
potential
best
class
topical
inhibitor
plaque
psoriasis
affects
approximately
million
patients
phase
trials
topline
data
anticipated
first
quarter
new
drug
application
nda
submission
anticipated
end
westlake
village
globe
newswire
arcutis
biotherapeutics
nasdaq
arqt
biopharmaceutical
company
focused
developing
commercializing
treatments
unmet
needs
dermatological
diseases
conditions
today
announced
completion
enrollment
company
pivotal
phase
clinical
trials
evaluating
topical
roflumilast
cream
potential
topical
treatment
plaque
psoriasis
patients
plaque
psoriasis
common
skin
disease
desperate
new
topical
options
unlike
existing
treatments
require
make
efficacy
safety
tolerability
said
patrick
burnett
faad
arcutis
chief
medical
officer
delighted
complete
enrollment
pivotal
phase
clinical
trials
evaluating
roflumilast
cream
potential
daily
topical
treatment
plaque
psoriasis
approved
believe
roflumilast
cream
potential
eliminate
need
dermatologists
patients
compromise
efficacy
safety
two
separate
prior
phase
studies
roflumilast
cream
demonstrated
statistically
significant
symptomatic
improvements
safety
tolerability
profile
supports
chronic
use
ability
use
body
areas
updating
guidance
plan
announce
topline
data
pivotal
phase
trials
first
quarter
positive
anticipate
submission
nda
fda
end
arcutis
recently
announced
positive
preliminary
results
first
cohort
ongoing
phase
safety
study
psoriasis
supporting
belief
roflumilast
cream
used
chronically
addition
new
england
journal
medicine
published
results
randomized
phase
study
roflumilast
cream
plaque
psoriasis
trials
p
de
inhibition
r
oflumilast
anagement
plaque
psorias
one
two
identical
phase
randomized
parallel
studies
roflumilast
cream
vehicle
cream
applied
daily
weeks
subjects
age
years
mild
moderate
severe
chronic
plaque
psoriasis
involving
body
surface
area
enrolled
subjects
enrolled
subjects
primary
endpoint
studies
investigator
global
assessment
iga
success
defined
iga
score
clear
almost
clear
least
improvement
baseline
week
iga
score
multiple
secondary
endpoints
also
evaluated
including
intertriginous
iga
success
improvements
psoriasis
area
severity
index
pasi
itch
measured
worst
rating
scale
patient
perceptions
symptoms
measured
psoriasis
symptoms
diary
psd
company
anticipates
topline
data
phase
studies
first
quarter
positive
anticipates
submission
nda
fda
end
topical
roflumilast
cream
roflumilast
cream
topical
cream
formulation
highly
potent
selective
inhibitor
roflumilast
roflumilast
approved
food
drug
administration
fda
oral
treatment
reduce
risk
exacerbations
chronic
obstructive
pulmonary
disease
copd
since
roflumilast
shown
greater
potency
two
inhibitors
intracellular
enzyme
increases
production
mediators
decreases
production
mediators
implicated
wide
range
inflammatory
diseases
including
psoriasis
eczema
copd
established
target
dermatology
inhibitors
approved
fda
topical
treatment
atopic
dermatitis
systemic
treatment
plaque
psoriasis
psoriasis
psoriasis
common
skin
disease
affects
approximately
million
patients
united
states
patients
develop
plaque
psoriasis
characterized
raised
red
areas
skin
covered
silver
white
layer
scale
psoriatic
plaques
appear
area
body
often
appear
scalp
knees
elbows
trunk
limbs
often
itchy
sometimes
painful
plaques
certain
anatomical
areas
present
particular
treatment
challenges
including
face
elbows
knees
scalp
intertriginous
regions
groin
axillae
inframammary
areas
arcutis
bioscience
applied
skin
arcutis
biotherapeutics
nasdaq
arqt
biopharmaceutical
company
focused
developing
commercializing
treatments
unmet
needs
dermatological
diseases
conditions
company
leveraging
recent
advances
immunology
inflammation
develop
differentiated
therapies
biologically
validated
targets
solve
persistent
treatment
challenges
serious
diseases
skin
arcutis
robust
pipeline
includes
four
novel
drug
candidates
currently
development
range
inflammatory
dermatological
conditions
company
lead
product
candidate
topical
roflumilast
potential
revitalize
standard
care
plaque
psoriasis
atopic
dermatitis
scalp
psoriasis
seborrheic
dermatitis
information
visit
https
follow
company
linkedin
twitter
forward
looking
statements
press
release
contains
statements
including
among
others
statements
regarding
roflumilast
cream
potential
psoriasis
treatment
expectations
regard
timing
clinical
data
anticipated
first
quarter
nda
submission
end
statements
involve
substantial
known
unknown
risks
uncertainties
factors
may
cause
actual
results
levels
activity
performance
achievements
materially
different
information
expressed
implied
statements
place
undue
reliance
statements
risks
uncertainties
may
cause
actual
results
differ
include
risks
inherent
clinical
development
process
regulatory
approval
process
timing
regulatory
filings
ability
defend
intellectual
property
description
risks
uncertainties
applicable
business
see
risk
factors
section
form
filed
securities
exchange
commission
sec
may
well
subsequent
filings
sec
undertake
obligation
revise
update
information
herein
reflect
events
circumstances
future
even
new
information
becomes
available
contact
heather
rowe
armstrong
vice
president
investor
relations
corporate
communications
harmstrong
ext
